FineHeart Secures $40.7M in Series C to Advance FlowMaker®, a Next-Gen Implantable Heart Failure Therapy

Recently,FineHeartAnnounce, completed First Closing of Series C Financing, the first phase of this round of fundraising $40.7 million (approximately RMB280 million）, for advancing its next-generation implantable device for heart failure treatmentFlowMaker®The clinical and industrialization process.
Following the completion of this round of financing, FineHeart has cumulatively raised approximately$96.6 millionFunding support.

This round of financing not only provides direct financial support for the company's subsequent R&D and commercialization but also serves as a catalyst.IPCEI Tech4CureAn important lever for public funding of the project. According to the disclosure, FineHeart, as one of the core participants in the project, will also receive€48 millionThe non-dilutive funding is used to support the construction of the key technology system for active implantable medical devices (AIMD) in Europe.

# Focus on Heart Failure Treatment: The Technical Pathway of Next-Generation Implantable Devices

FineHeart's Core Product FlowMaker, is a product designed for patients with severe heart failure.Fully Implantable Cardiac Output Acceleration DeviceUnlike the current mainstream left ventricular assist device (LVAD), the design goal of FlowMaker is not to completely replace the heart's pumping function, but ratherWorking in coordination with the heart's own contraction rhythm, providing auxiliary support while preserving native heart function.

In terms of technology roadmap selection, FineHeart has positioned FlowMaker as aAn auxiliary solution closer to the physiological state. The device is fully implanted in the ventricle, does not require an aortic bypass, and throughTranscutaneous Energy Transfer (TET) SystemPerforming wireless charging avoids the risk of infection associated with the long-term reliance on external power supply interfaces in traditional LVADs. The company stated that this design is expected to significantly improve patients' long-term quality of life while reducing invasiveness.

# Clinical and Industrial Progress: From Concept Validation to the Real World

FineHeart announced that its FlowMaker system received regulatory approval in the middle of last year and has officially launched.First-in-Human Clinical Trial (First-in-Human). This milestone marks the transition of the technology from a long-term research and development phase into a validation cycle focused on the accumulation of clinical data.

With the support of this round of financing and IPCEI Tech4Cure funding, the company's future R&D focus will be on the common challenges long faced by active implantable medical devices, including:
Further miniaturization of the power system, significant reduction in overall energy consumption, and enhanced reliability and durability of the implant system under long-term use conditions.
These technical breakthroughs not only serve FlowMaker itself but are also regarded as an important foundation for building the European AIMD technology system.

# Market Background: Another Possibility Beyond the LVAD System

In the current field of heart failure auxiliary treatment, the market has long been dominated by traditional LVAD products, among which...AbbottUnder its umbrellaHeartMateThe series is the most representative. At the same time, emerging companies such as CorWave and BrioHealth are also attempting to enter this high-barrier track from different technological approaches.

FineHeart has chosen a path that emphasizes "collaboration rather than replacement." The company believes that by reducing system invasiveness, lowering energy consumption, and simplifying the long-term management burden, FlowMaker is expected to cover some patients who are not currently well-served by traditional LVADs. According to company disclosures, its initial focus will be on severe heart failure patients for whom existing treatment options are not applicable or who have not yet received effective assisted treatment.

# Company Overview: From Scientific Research Transformation to Industrial Promotion

FineHeart is a clinical-stage medical device company headquartered in Bordeaux and Toulouse, France, focusing on the research and development of cardiac implantable systems. The company was co-founded by Arnaud Mascarell and several experts in the fields of cardiac surgery and electrophysiology, and has established coverage across27 patent families, 160 patentsInternational intellectual property portfolio.

The company estimates that the potential market size targeted by FlowMaker exceeds5 billion euros, which can cover approximately in the long term200,000 peoplePatients with severe heart failure. At the current stage, FineHeart's core objectives remain focused on clinical validation, improving system reliability, and laying the engineering and manufacturing groundwork for subsequent commercialization.

# Conclusion

Against the backdrop of continuous breakthroughs in heart failure treatment, FineHeart's current round of financing reflects not only the progress of a single product but also Europe's long-term strategy to strengthen the industrial chain and technological system in the high-end implantable medical device field.
As FlowMaker enters the clinical stage, the key to the next phase will depend on the speed of accumulating real-world data, as well as its ability to demonstrate a balance between safety, durability, and patient benefits.